Samsung Biologics Decides on 3 Trillion KRW Rights Offering to Shareholders

[Asia Economy Reporter Lee Seon-ae] Samsung Biologics announced on the 28th that it has decided to proceed with a rights offering followed by a general public offering of unsubscribed shares to raise a total of 3 trillion KRW in funds, including 1.798 trillion KRW for facility capital and 1.2024 trillion KRW for acquiring securities of other corporations.

It will newly issue 5,009,000 common shares, which corresponds to 7.6% of the 66,165,000 shares outstanding before the capital increase. The planned issue price per new share is 599,000 KRW, and the expected listing date of the new shares is April 28.

Meanwhile, Samsung Biologics also announced on the same day that it has decided to acquire all 10,341,852 shares of its subsidiary Samsung Bioepis held by Biogen for 2.7655 trillion KRW. After the acquisition, Samsung Biologics' ownership stake will be 100%.